Evaluation of diuretic therapy response in patients with pulmonary edema in the emergency department using the Reverse-FALLS protocol: A prospective observational study Authors: Ömer Faruk Koç, Elif Betül Balci, Başar Cander, Bahadir Taslidere, Ertan Sönmez Published: 2026 ABSTRACT Cardiogenic pulmonary edema (CPE) is a serious condition that can result in impaired gas exchange and acute respiratory failure, often leading to high mortality. Diuretics are considered to be the cornerstone of CPE treatment. The doses of furosemide should be individualized according to the patient status and response. Lung ultrasonography has emerged as a reliable bedside tool for diagnosing and monitoring pulmonary congestion. By considering the extent of extravascular lung water and the inferior vena cava (IVC) size, clinicians can obtain objective data to guide them in determining the appropriate level of diuresis for the safe and effective treatment of pulmonary edema. However, data on the use of structured ultrasound protocols, such as the Reverse-FALLS protocol, to guide and monitor diuretic therapy in the emergency department are limited. This prospective, single-center observational study was conducted between April 1 and June 30, 2023, in an emergency department. Adult patients diagnosed with acute CPE were included. Bedside lung ultrasonography and IVC measurements were performed using the Reverse-FALLS protocol before and after intravenous loop diuretic therapy. The number of B-lines in 4 lung regions and IVC diameter changes were recorded. The primary outcome was the change in B-line counts following diuretic treatment. Secondary outcomes included IVC diameter changes and clinical outcomes. A total of 40 patients (mean age 73.7 ± 12.7 years; 65% female) were included. After diuretic therapy, 82.5% of patients demonstrated a significant reduction in B-lines on lung ultrasonography. B-line counts decreased significantly in all lung regions (right upper P = .005, right lower P = .013, left upper P < .001, left lower P < .001). The mean interval between ultrasound assessments was 6.2 ± 3.4 hours. Changes in IVC diameter were not statistically significant (P = .061). Higher brain natriuretic peptide levels were significantly associated with worse clinical outcomes (P = .021). Bedside lung ultrasonography using the Reverse-FALLS protocol effectively demonstrated a reduction in pulmonary congestion following diuretic therapy in patients with CPE. Monitoring B-line changes may allow individualized diuretic management without significant intravascular volume depletion, supporting the clinical utility of ultrasound-guided treatment in the emergency department. 1. Introduction Cardiogenic pulmonary edema (CPE) is a common and life-threatening condition. It is a major cause of acute respiratory failure. Acute respiratory failure develops when the respiratory system is unable to sustain adequate gas exchange, resulting in hypoxemia with or without hypercapnia.[1] Patient prognosis in CPE is strongly influenced by the severity of underlying disease, with in-hospital mortality rates ranging from 10% to 30%, particularly in those with acute heart failure or acute coronary syndrome.[2] In patients with CPE, rapid accumulation of extravascular lung water due to elevated cardiac filling pressures leads to impaired oxygen diffusion and progressive hypoxia if not promptly recognized and treated.[3] The cornerstone of CPE management is rapid decongestion, primarily achieved through loop diuretics, along with adjunctive therapies such as vasodilators and ventilatory support.[4] However, determining the optimal intensity of diuretic therapy remains challenging, as excessive diuresis may lead to intravascular volume depletion and renal dysfunction, while insufficient treatment may result in persistent pulmonary congestion and poor clinical outcomes.[5] Therefore, objective, bedside tools that can simultaneously assess extravascular and intravascular volume status are of critical importance in guiding individualized treatment. Lung ultrasonography has emerged as a reliable, noninvasive method for the assessment of pulmonary congestion.[6] The presence and number of B-lines correlate strongly with extravascular lung water and have demonstrated high diagnostic accuracy in acute CPE. The high sensitivity (94.1%) and specificity (92.4%) of B-lines in diagnosing acute CPE underscores the reliability of this technique.[7] Lung ultrasonography is a practical bedside method that allows clinicians to evaluate fluid status in real time. Assessment of the anterior chest provides direct information about extravascular pulmonary edema, which is crucial for monitoring response to treatment. In parallel, inferior vena cava (IVC) ultrasonography reflects intravascular volume and venous congestion, helping clinicians balance effective decongestion with the risk of volume depletion.[8] The Reverse-FALLS protocol combines lung ultrasonography with IVC assessment, providing a structured approach that focuses primarily on evaluating pulmonary congestion. The Reverse-FALLS protocol in CPE focuses not on the presence of fluid, but on whether excess fluid is being effectively reduced by treatment.[9] Despite growing evidence supporting lung ultrasonography in the diagnosis of CPE, data on the use of structured protocols such as Reverse-FALLS to monitor and guide diuretic therapy in the emergency department are limited. In particular, there is a lack of prospective studies evaluating dynamic changes in B-lines and IVC measurements following diuretic treatment and their association with short-term clinical outcomes.[10] This study aimed to explore the practical value of bedside lung ultrasonography using the Reverse-FALLS protocol for the diagnosis and follow-up of acute CPE, and to evaluate its role in supporting diuretic treatment decisions in the emergency department. 2. Material and methods This study was approved by the Noninterventional Clinical Research Ethics Committee of Bezmialem Vakif University. All procedures were conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrollment. 2.1. Study design, setting, and duration This was a prospective, single-center observational study conducted in the emergency department of a tertiary care university hospital between April 1, 2023, and June 30, 2023. 2.2. Study population Adult patients aged 18 years and older who presented to the emergency department with acute-onset dyspnea suggestive of pulmonary edema were screened for eligibility. Patients were included if clinical evaluation and chest imaging supported a diagnosis of acute CPE and if the treating physician decided to initiate intravenous diuretic therapy as part of routine management. Patients were excluded if they were under 18 years of age, had no confirmed diagnosis of heart failure, or did not receive intravenous furosemide during their emergency department stay. In addition, patients with missing clinical or ultrasonographic data, as well as those who declined to participate, were not included in the final analysis (Fig. 1). Patient flowchart. 2.3. Study objectives The primary objective of this study was to evaluate the role of bedside lung ultrasonography using the Reverse-FALLS protocol in monitoring response to diuretic therapy in patients with acute CPE. The secondary objectives were: To assess changes in B-line number following diuretic administration To assess changes in B-line number following diuretic administration To evaluate IVC diameter changes during treatment To evaluate IVC diameter changes during treatment To explore the feasibility of using the Reverse-FALLS protocol for bedside treatment guidance in the emergency department To explore the feasibility of using the Reverse-FALLS protocol for bedside treatment guidance in the emergency department 2.4. Reverse-FALLS protocol – step-by-step In this study, the response to diuretic therapy in patients with acute CPE was evaluated using the Reverse-FALLS protocol. This protocol is based on the simultaneous ultrasonographic assessment of extravascular volume status, reflected by lung B-lines, and intravascular volume status, assessed by IVC measurements. All examinations were performed with patients in a 30° to 45° semi-Fowler position. Before diuretic administration, an 8-zone lung ultrasound was performed and the number of B-lines was recorded for each zone; the presence of 3 or more B-lines in a zone was considered indicative of pulmonary edema. Intravascular volume status was evaluated by measuring the IVC in the subcostal long-axis view, approximately 1 to 2 cm distal to the hepatic vein junction, and calculating the IVC collapsibility index from maximum and minimum diameters. After diuretic therapy, ultrasonographic assessments were repeated serially using the same lung zones and identical IVC measurement points. Posttreatment ultrasound was performed at the time when a clinical response was documented, defined as improvement in dyspnea accompanied by an increase in oxygen saturation and a decrease in respiratory rate. The time between the initial and follow-up ultrasound assessments was also recorded. Treatment response was primarily assessed by a reduction in B-line count, while safety was monitored through changes in IVC diameter and collapsibility index to detect potential excessive intravascular volume depletion. All ultrasonographic measurements were performed by physicians trained in lung and basic critical care ultrasonography and were recorded in accordance with the standardized study protocol.[11] 2.5. Details of diuretic therapy In patients with acute CPE, intravenous furosemide was used as diuretic therapy. An initial dose of 20 to 40 mg IV was administered, while higher doses of 40 to 80 mg IV were preferred in patients with prior diuretic use or marked volume overload. Treatment was initiated immediately after the baseline assessment, and a repeat dose was administered 60 to 120 minutes later if the clinical response was considered insufficient.[12] According to the European Society of Cardiology guidelines, intravenous loop diuretics are the 1st-line treatment for pulmonary edema. Furosemide, a common loop diuretic, starts working within 1 to 2 hours, and its effects can last up to 6 hours. 2.6. Clinical variables and definitions Clinical parameters were recorded at the time of emergency department admission and after treatment. Body temperature was measured tympanically, oxygen saturation was assessed by pulse oximetry, and blood pressure was measured using a noninvasive method. Clinical improvement was defined as relief of dyspnea together with an increase in oxygen saturation and a reduction in respiratory rate. Follow-up ultrasonography was performed at the time this clinical response was observed. 2.7. Statistical analysis Statistical analysis of the data was performed using Statistical Package for the Social Sciences, version 21.0 (International Business Machines Corporation). Normality of continuous variables was initially assessed using the Kolmogorov–Smirnov and Shapiro–Wilk tests. For descriptive analysis, measures of central tendency and dispersion, including mean, median, minimum, maximum, standard deviation, and frequency, were calculated as appropriate. Continuous variables with a normal distribution are presented as mean ± standard deviation, whereas nonnormally distributed variables are expressed as median (minimum–maximum). Categorical variables are reported as frequencies and percentages. Comparisons of continuous variables between independent groups were performed using the independent samples t test for normally distributed data and the Mann–Whitney U test for nonnormally distributed data. For paired comparisons between ultrasonographic measurements obtained at presentation and after treatment, the Wilcoxon signed-rank test was used. All results were evaluated within a 95% confidence interval, and a P value <.05 was considered statistically significant. For reference, assuming a moderate effect size (dz = 0.50) and a 2-sided significance level of α = 0.05, a minimum sample size of approximately 34 patients would be required to achieve 80% statistical power, a threshold that was exceeded by the current study population. 3. Results A total of 40 patients were included in the study, with a mean age of 73.7 ± 12.7 years. Of these, 26 patients (65%) were female and 14 (35%) were male. Regarding clinical outcomes, 35 patients (87.5%) were discharged from the emergency department, 2 patients (5%) were admitted to inpatient wards, 2 patients (5%) were transferred to the intensive care unit, and 1 patient (2.5%) died. The mean time interval between the baseline and posttreatment ultrasonographic examinations was 6.2 ± 3.4 hours. 3.1. Ultrasonographic findings before and after diuretic therapy Baseline and posttreatment lung ultrasonography findings according to lung localization are summarized in Table 1. At presentation, a high B-line burden (≥4 B-lines) was observed in the majority of lung regions, indicating significant pulmonary congestion. Following diuretic therapy, a visible shift toward lower B-line categories (0–1 and 2–3 B-lines) was observed across all lung zones. Table 1Ultrasonography results according to localization before and after treatment.B-line countRight upperRight lowerLeft upperLeft lowerUltrasonography performed during the 1st application0–156572–3101815164 and above25162017IVC diameter difference8.4 ± 4.3 mmUltrasonography performed during posttreatment0–181414202–3191619144 and above131076IVC diameter difference6.8 ± 3.6 mmIVC = inferior vena cava. Ultrasonography results according to localization before and after treatment. IVC = inferior vena cava. Paired comparisons of ultrasonographic findings before and after treatment are presented in Table 2. A significant reduction in B-line counts was observed in 82.5% of patients after diuretic therapy. When analyzed by lung region, B-line counts decreased significantly in the right upper zone (P = .005), right lower zone (P = .013), left upper zone (P < .001), and left lower zone (P < .001), based on Wilcoxon signed-rank testing. These findings indicate a consistent and statistically significant reduction in extravascular lung water following treatment. Table 2Ultrasonography results before and after treatment.ParameterChangeNumber of individualsP valueInferior vena cavaDiameter differenceDecreased25.061*Increased13Stable2B-line countRight upperDecreased16.005*Increased4Stable20Right lowerDecreased17.013*Increased6Stable17Left upperDecreased21<.001*Increased2Stable17Left lowerDecreased20<.001*Increased2Stable17P < .05 was considered statistically significant.*Wilcoxon test was used. Ultrasonography results before and after treatment. P < .05 was considered statistically significant. Wilcoxon test was used. In contrast, changes in intravascular volume parameters were less pronounced. Although the IVC diameter difference between inspiration and expiration decreased in 25 patients, increased in 13 patients, and remained stable in 2 patients, the overall change in IVC diameter did not reach statistical significance (P = .061, Table 2). 3.2. Laboratory findings and clinical outcomes Comparisons of demographic characteristics, vital signs, laboratory parameters, and ultrasonographic measurements according to clinical outcome (discharged vs critical outcome) are shown in Table 3. There were no statistically significant differences between groups in terms of age, systolic or diastolic blood pressure, pulse rate, respiratory rate, body temperature, oxygen saturation, or most laboratory parameters, including hemoglobin, hematocrit, white blood cell count, platelet count, electrolytes, renal function markers, glucose, and troponin levels (all P > .05). Table 3Laboratory results and clinical findings.DischargedCritical outcomeP valueAge (years)73.5 ± 12.774.8 ± 14.84*SBP (mm Hg)169.6 ± 34.7171.2 ± 29.5.925*DBP (mm Hg)83.4 ± 2086.8 ± 14.3.719*Pulse (/min)103.1 ± 26.684 ± 11.7.124*Respiratory rate (/min)20 (18–29)20 (18–20).346**Temperature (°C)36.6 (35–38.5)36.7 (36.4–37.2).447**Saturation (%)92 (64–100)92 (86–100).743**HGB (g/dL)10.9 ± 2.310.8 ± 1.9.909*HTC34.6 ± 7.232.3 ± 6.4.509*WBC (103/mm3)9.1 (4.9–20.8)8.3 (3.7–12.9).379**PLT (103/mm3)293.2 ± 98.7225.4 ± 67.147*Sodium (mEq/L)137 (123–143)135 (115–141).387**Glucose (mg/dL)146 (73–483)152 (115–219).984**Urea (mg/dL)56 (28.9–137)137 (41–169).115**Creatinine (mg/dL)1.1 (0.5–8.2)2 (0.8–3.5).336**Troponin (ng/mL)18 (2.4–1007.3)19 (13.8–26.4).854**BNP (pg/mL)405.3 (54.8–7555)1241.1 (694.3–1529) .021 ** IVC (initial)7.8 (2.7–19.5)10.6 (6.6–11.5).17**IVC (final)5 (1.7–15.6)8.4 (6.1–16.1).146**Critical outcome: Patients who were hospitalized, admitted to the intensive care unit, or died. Statistical significance was set at P < .05.BNP = brain natriuretic peptide, DBP = diastolic blood pressure, HGB = hemoglobin, HTC = hematocrit, IVC = inferior vena cava, PLT = platelet, SBP = systolic blood pressure, WBC = white blood cells.*An independent sample t test was used.**Mann–Whitney U test was used. Laboratory results and clinical findings. Critical outcome: Patients who were hospitalized, admitted to the intensive care unit, or died. Statistical significance was set at P < .05. BNP = brain natriuretic peptide, DBP = diastolic blood pressure, HGB = hemoglobin, HTC = hematocrit, IVC = inferior vena cava, PLT = platelet, SBP = systolic blood pressure, WBC = white blood cells. An independent sample t test was used. Mann–Whitney U test was used. However, brain natriuretic peptide (BNP) levels were significantly associated with clinical outcomes. Patients who were discharged had significantly lower BNP levels compared with those who experienced a critical outcome (405.3 vs 1241.1 pg/mL, P = .021, Table 3). Higher BNP levels were therefore associated with worse short-term clinical outcomes in this cohort. Initial and posttreatment IVC diameters did not differ significantly between outcome groups (P = .17 and P = .146, respectively; Table 3). 4. Discussion Our results show that early response to diuretic therapy can be reliably monitored through a reduction in B-lines on lung ultrasound. In contrast, IVC measurements do not demonstrate significant short-term changes. The observation of a marked reduction in B-line counts in 82.5% of patients following diuretic therapy suggests that treatment response can be reliably and dynamically monitored using lung ultrasonography. In the retrospective observational study by Ienghong et al, B-line analysis assessed by lung ultrasonography in patients with pulmonary edema was found to be significantly associated with earlier initiation of diuretic therapy.[13] Miglioranza et al demonstrated that assessment of B-lines by lung ultrasonography is effective in the evaluation of acute pulmonary edema, as it reflects the degree of pulmonary congestion and allows rapid optimization of therapy in patients at risk of acute decompensation.[14] Mayr et al, in their systematic search, emphasized that assessing extravascular hydration status through the detection of B-lines is a suitable, cost-effective, and accessible tool.[15] Our study goes beyond demonstrating the diagnostic value of B-line reduction in acute pulmonary edema by focusing on dynamic treatment monitoring. By evaluating serial changes in B-line burden following diuretic administration, we quantitatively assessed the physiological response to decongestive therapy. Importantly, our findings indicate that significant reductions in B-lines can be detected shortly after diuretic treatment, even in the absence of marked changes in intravascular volume parameters. In the study conducted by Cortellaro et al, lung ultrasonography showed a marked early reduction in the B-score within the 1st 3 hours, which continued to decrease up to 24 hours in parallel with clinical, respiratory, and hemodynamic improvement. At 24 hours, B-line clearance was observed in 75% of apical lung regions, whereas only 38% of basal regions showed resolution.[10] In our study, a statistically significant reduction in B-line counts was observed in both upper and lower lung zones following diuretic therapy. However, this reduction was more consistent and pronounced in the upper zones. Decreases in B-line numbers in the right and left upper lung regions reached statistical significance, whereas the lower zones, despite also showing significant improvement, more frequently exhibited persistent residual B-lines. This regional distribution likely reflects gravity-dependent fluid accumulation and the slower mobilization of interstitial fluid in the basal lung areas. Our findings suggest that, in the early phase of treatment, diuretic therapy preferentially reduces pulmonary congestion in the upper lung zones, while decongestion of the lower zones occurs more gradually. Therefore, assessing treatment response by focusing solely on basal lung regions may be misleading, and a combined, serial evaluation of both upper and lower lung zones provides a more clinically meaningful assessment of pulmonary decongestion. Current expert guidelines for acute heart failure, including CPE, assume that a meaningful natriuretic and diuretic response should occur within the 1st 2 to 6 hours following intravenous bolus diuretic administration.[12] Furosemide has a terminal half-life of approximately 2 hours, and its therapeutic effects generally persist for 6 to 8 hours. Following intravenous administration, the onset of diuretic action is typically observed within 35 to 45 minutes.[16] In our study, both clinical and ultrasonographic improvement after diuretic therapy was observed within a mean time of 6.2 hours. Importantly, while the pharmacokinetics and overall duration of action of furosemide are well described in the literature, there are no studies that clearly define the timing of treatment response using objective clinical and ultrasonographic measures. According to previous studies, the diameter and collapsibility index of the IVC provide critical information about a patient fluid balance. An IVC collapsibility index of ≥0.5, indicates fluid shift and redistribution to the pulmonary vascular space, while an IVC diameter <1.5 cm suggests fluid deficiency, and a diameter >2.5 cm indicates fluid overload.[17,18] Several studies have demonstrated that diuretic therapy in acute CPE leads to a consistent and significant reduction in IVC diameter.[19,20] The results obtained by Katzarski et al suggest that changes in IVC diameter following diuretic therapy may not be permanent. This is because the fluid redistribution from the capacitance vessels and extravascular spaces to the central veins can gradually counterbalance the initial reduction. This finding highlights the need for careful interpretation of IVC diameter measurements when assessing the effectiveness of diuretic therapy.[21] In clinical practice, despite diuretic therapy, a persistent lack of change in IVC diameter often requires reassessment of the patient volume status, evaluation of diuretic resistance, and consideration of alternative or adjunctive treatments, such as increasing the diuretic dose, switching to a different diuretic class, or using ultrafiltration. This situation is a critical indicator not only for assessing the effectiveness of treatment but also for understanding the underlying pathophysiology. In our study, despite the lack of a statistically significant change in IVC diameter after diuretic treatment (P = .061), the significant reduction in B-lines suggested that pulmonary congestion or interstitial fluid decreased without a marked change in central venous pressure or intravascular volume. This finding suggests that diuretics may effectively reduce pulmonary interstitial fluid without significantly lowering intravascular volume. Rather than fluid removal, fluid redistribution may alleviate pulmonary congestion symptoms without causing a significant change in IVC diameter. This may be related to the underlying diuretic resistance, where only partial fluid movement occurs, preventing a meaningful reduction in central venous pressure. As a result, a decrease in pulmonary congestion can occur even when the volume is not sufficiently reduced to affect IVC diameter. In patients with diuretic resistance, this situation may indicate an inadequate response to treatment and suggests the need to evaluate alternative treatment strategies. Future studies should explore the mechanisms of diuretic resistance in this patient group and investigate methods to improve treatment response. The key finding of this study is that early response to diuretic therapy in acute CPE can be reliably detected by a reduction in lung ultrasound B-lines, while IVC parameters remain largely unchanged in the short term. Clinical and ultrasonographic improvement occurred within a mean of 6.2 hours, highlighting lung ultrasound as a sensitive tool for early treatment monitoring in the emergency department. While the pharmacokinetics and general duration of action of furosemide are well established, previous studies have not clearly defined the temporal window of therapeutic response using objective clinical and ultrasonographic parameters. Our work addresses this gap by demonstrating that meaningful clinical and lung ultrasound improvement can be detected within a mean of 6.2 hours following diuretic therapy. 4.1. Limitation This study has several limitations that should be considered. The prospective, single-center design may restrict the generalizability of the results and carries an inherent risk of selection bias. In addition, the relatively small sample size limits statistical power, particularly for subgroup and outcome-based analyses. Diuretic therapy was not standardized with respect to dose, timing, or repeat administration and was instead determined by the treating physician clinical judgment. While this reflects real-world practice, it also introduces heterogeneity in treatment exposure. Ultrasonographic evaluations were performed at predefined but variable time intervals rather than at fixed time points, which may have influenced the magnitude of the observed changes. Moreover, the absence of invasive hemodynamic measurements prevented direct comparison with gold-standard assessments of intravascular volume or filling pressures. Finally, the study focused on short-term clinical and ultrasonographic responses, and long-term outcomes were not assessed. These limitations should be taken into account when interpreting the findings, and future prospective, multicenter studies with standardized treatment protocols are needed to confirm and extend our results. 5. Conclusions By focusing on dynamic, serial changes in B-line burden rather than static diagnostic assessment, this study extends the role of lung ultrasound from diagnosis to real-time treatment monitoring and offers a practical framework for early response assessment in the emergency department. Author contributions Conceptualization: Ömer Faruk Koç, Bahadir Taslidere Data curation: Ömer Faruk Koç, Bahadir Taslidere Formal analysis: Ömer Faruk Koç, Başar Cander, Bahadir Taslidere Investigation: Bahadir Taslidere Methodology: Ömer Faruk Koç, Bahadir Taslidere Project administration: Ömer Faruk Koç, Elif Betül Balci Resources: Ömer Faruk Koç Supervision: Ömer Faruk Koç, Başar Cander, Bahadir Taslidere, Ertan Sönmez Validation: Ömer Faruk Koç, Elif Betül Balci, Başar Cander, Bahadir Taslidere Visualization: Ömer Faruk Koç Writing – original draft: Ömer Faruk Koç, Elif Betül Balci, Bahadir Taslidere Writing – review & editing: Elif Betül Balci, Bahadir Taslidere